A 92.6% reduction in the list price of tafamidis—an effective but ultimately unaffordable drug designed to treat transthyretin amyloid cardiomyopathy—would be required to make the medication accessible to the average heart patient, researchers reported in Circulation Feb. 12.

Medtronic and the FDA were both aware of battery and wire connection defects in a now-recalled heart failure pacemaker for over a year before patients developed serious side effects, according to a report published in JAMA Internal Medicine.

Research out of Ireland suggests end-of-life care needs will nearly double over the next three decades, corresponding to an increase of 84% by 2046.

Despite other quality of life improvements, heart patients supported by left ventricular assist devices face “severely impaired” exercise capacity, according to a study published online in JACC: Heart Failure.

Lab-growing cardiomyocytes have been transplanted into a human patient for the first time in medical history, according to a report from the Japan Times.

Scientists have uncovered a potential new treatment for heart failure with preserved ejection fraction (HFpEF)—and it’s one that already exists.

Black patients at a heightened risk for heart disease cut their CV mortality risk by 11% in a study that explored the cardiac benefits of the Transcendental Meditation technique.

A cross-structural analysis published in Mayo Clinic Proceedings this January independently links diabetes to the development of heart failure, suggesting diabetic cardiomyopathy is a real—and growing—issue in the U.S.

Drugmaker AstraZeneca announced Jan. 6 that its SGLT2 inhibitor dapagliflozin, sold commercially as Farxiga, had been granted Priority Review by the FDA for patients with heart failure with reduced ejection fraction.

Diagnosed cases of chronic heart failure are expected to number 32 million by 2028, according to a report from analytics company GlobalData.

Beta-blocker use was linked to an increased risk of heart failure hospitalizations in a recent study of patients with “stiff heart” HF—a concerning finding considering the majority of such patients take the drugs as part of their care regimen.

Novoheart, a Vancouver-based stem cell biotech company, is pairing with biopharmaceutical giant AstraZeneca to develop the world’s first human-specific in vitro functional model of heart failure with preserved ejection fraction.